Written by www.hartgroup.org
A comprehensive review of the research literature has confirmed what many doctors have been claiming for a long time: ivermectin is an effective treatment of COVID-19. The peer-reviewed study, published in the American Journal of Therapeutics, examined a huge amount of evidence, including 18 randomised controlled treatment trials.
The authors found that ivermectin not only reduces ICU admissions and mortality rates for hospitalised patients, but can also prevent deterioration for those with mild to moderate disease.
Ivermectin, an anti-parasitic drug, has been around for almost 40 years, is cheap, widely available, and benefits from an excellent safety record. Curiously, regulatory agencies, including those in the UK, have been reluctant to recommend it for treatment of COVID-19.
There have even been instances of social media platforms removing content that has promoted ivermectin. Even more concerningly, a paper describing its benefits had successfully navigated peer-review at a mainstream journal (Frontiers in Pharmacology), only to be pulled at the last minute for reasons four of the guest editors found disturbing enough for them to resign in protest (their letter can be found here.)
However, the authors of the review in American Journal of Therapeutics could not be more emphatic in their recommendation that it be ‘globally and systematically deployed in the prevention and treatment of COVID-19’.
There are now no legitimate reasons not to endorse ivermectin as a mainstream intervention to fight any future emergence of the pandemic. In fact, in the light of the compelling evidence, authorities that do not actively promote ivermectin should be asked why they are not doing this. As mentioned in last week’s bulletin, the Indian authorities are now promoting the use of home treatment using ivermectin in early COVID-19.
Read more at www.hartgroup.org
Please Donate Below To Support Our Ongoing Work To Expose The Lies About COVID19
PRINCIPIA SCIENTIFIC INTERNATIONAL, legally registered in the UK as a company incorporated for charitable purposes. Head Office: 27 Old Gloucester Street, London WC1N 3AX.
Trackback from your site.